4 346

Cited 2 times in

Assessment of Adjuvant Trastuzumab-Associated Cardiac Toxicity in Korean Patients with Breast Cancer: A Single-Center Analysis

 Chihwan Cha  ;  Sung Gwe Ahn  ;  Hak Min Lee  ;  Hak Woo Lee  ;  Seung Ah Lee  ;  Joon Jeong 
 ONCOLOGY, Vol.85(4) : 228-234, 2013 
Journal Title
Issue Date
Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects* ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents/adverse effects* ; Antineoplastic Agents/therapeutic use ; Breast Neoplasms/drug therapy* ; Chemotherapy, Adjuvant/adverse effects ; Female ; Follow-Up Studies ; Heart/drug effects* ; Heart Diseases/chemically induced* ; Heart Diseases/epidemiology ; Humans ; Incidence ; Middle Aged ; Prospective Studies ; Republic of Korea ; Risk Factors ; Stroke Volume ; Trastuzumab ; Ventricular Function, Left/physiology
Breast cancer ; Trastuzumab ; Cardiac toxicity ; Adjuvant treatment
Background: We performed this analysis to investigate the clinical presentation of trastuzumab-associated cardiac toxicity in Korean women. Method: 124 patients treated in a single institute from January 2006 to November 2011 with adjuvant trastuzumab therapy following primary surgery were identified from a database. We evaluated the cumulative incidence of cardiac toxicity, associated risk factors, and changes in cardiac function during trastuzumab treatment. Results: The median age of patients was 50 years (range 27-73). After 12 months of follow-up, the cumulative incidence of cardiac toxicity was 12.1% (grade I: 8.1%, grade II: 0.8%, grade III: 3.2%). In total, 4% of patients discontinued treatment due to cardiac dysfunction. The left ventricular ejection fraction (LVEF) recovered in all patients who discontinued or delayed treatment due to cardiac dysfunction following treatment discontinuation. The degree of the decrease in LVEF was large at 6 months after the initiation of treatment. A lower LVEF at baseline (<65%) was associated with cardiac toxicity. Conclusions: The low incidence of cardiac toxicity and the reversibility of cardiac dysfunction may validate the safety of trastuzumab treatment in Korean women with an acceptable baseline LVEF.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sung Gwe(안성귀) ORCID logo https://orcid.org/0000-0002-8778-9686
Lee, Hak Min(이학민)
Jeong, Joon(정준) ORCID logo https://orcid.org/0000-0003-0397-0005
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.